Arbutus Biopharma
ABUS
ABUS
172 hedge funds and large institutions have $587M invested in Arbutus Biopharma in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 45 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
4% more funds holding
Funds holding: 166 → 172 (+6)
1.8% more ownership
Funds ownership: 61.64% → 63.45% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Holders
172
Holding in Top 10
5
Calls
$14.3M
Puts
$4.77M
Top Buyers
| 1 | +$11.3M | |
| 2 | +$10.1M | |
| 3 | +$8.14M | |
| 4 |
TSC
Two Seas Capital
Rye,
New York
|
+$7.19M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$4.01M |
Top Sellers
| 1 | -$8.98M | |
| 2 | -$6.45M | |
| 3 | -$4.63M | |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$3.63M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.04M |
